Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew C T Fyfe

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Progress in Medicinal Chemistry|February 9, 2016
Non-systemic Intestine-Targeted DrugsMatthew C T Fyfe
Clinical Ophthalmology (Auckland, N.Z.)|March 13, 2019
A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye diseaseMike Taylor, George Ousler, Gail Torkildsen, et al.
Angewandte Chemie (International Ed. in English)|May 2, 2018
Supramolecular Daisy ChainsPeter R Ashton, Ian Baxter, Stuart J Cantrill, et al.
Inflammatory Bowel Diseases|April 23, 2016
Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative ColitisPaolo Biancheri, Martyn R Foster, Matthew C T Fyfe, et al.
Investigative Ophthalmology & Visual Science|April 7, 2018
Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory DisordersSuzanne Hagan, Matthew C T Fyfe, Boatemaa Ofori-Frimpong, et al.
Cell Metabolism|March 7, 2006
Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agentsHilary A Overton, Adam J Babbs, Sheila M Doel, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2005
Glucokinase-activating ureasArlindo L Castelhano, Hanqing Dong, Matthew C T Fyfe, et al.
Journal of Medicinal Chemistry|July 1, 2008
SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1Lisa S Bertram, Daniel Black, Paul H Briner, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Progress in Medicinal Chemistry|February 9, 2016
Non-systemic Intestine-Targeted DrugsMatthew C T Fyfe
Clinical Ophthalmology (Auckland, N.Z.)|March 13, 2019
A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye diseaseMike Taylor, George Ousler, Gail Torkildsen, et al.
Angewandte Chemie (International Ed. in English)|May 2, 2018
Supramolecular Daisy ChainsPeter R Ashton, Ian Baxter, Stuart J Cantrill, et al.
Inflammatory Bowel Diseases|April 23, 2016
Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative ColitisPaolo Biancheri, Martyn R Foster, Matthew C T Fyfe, et al.
Investigative Ophthalmology & Visual Science|April 7, 2018
Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory DisordersSuzanne Hagan, Matthew C T Fyfe, Boatemaa Ofori-Frimpong, et al.
Cell Metabolism|March 7, 2006
Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agentsHilary A Overton, Adam J Babbs, Sheila M Doel, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2005
Glucokinase-activating ureasArlindo L Castelhano, Hanqing Dong, Matthew C T Fyfe, et al.
Journal of Medicinal Chemistry|July 1, 2008
SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1Lisa S Bertram, Daniel Black, Paul H Briner, et al.
Pageof 1